Portuguese nanomedicine SME developing biosensing platforms for single-cell diagnostics and AI-driven cancer survivorship care.
RubyNanoMed is a Portuguese nanotechnology SME based in Braga specializing in nanoscale biosensing platforms and their application to clinical and research contexts. Their most distinctive work involves developing ultrasensitive biosensors capable of detecting and profiling cellular proteins at the single-cell level — a capability relevant to precision oncology and early diagnostics. They also bring expertise in AI-driven cancer survivorship tools, contributing to digital health systems that help patients and clinicians manage long-term care after treatment. As a small company operating at the intersection of nanotechnology, diagnostics, and digital health, they function as a specialist technology contributor within larger research consortia.
BIOCELLPHE (2021–2025) is explicitly about developing an ultrasensitive biosensing platform for multiplex cellular protein phenotyping at the single-cell level, which aligns directly with the company's name and presumed core technology.
PERSIST (2020–2023) focused on patient-centered survivorship care plans after cancer treatments using Big Data and AI, with RubyNanoMed contributing as a participant.
PERSIST keywords include interoperability and privacy/security and ethics, suggesting RubyNanoMed has worked on compliant data-sharing frameworks within digital health systems.
Both PERSIST and BIOCELLPHE target oncology applications — one from the care pathway side, one from the diagnostic/sensing side — indicating a deliberate focus on cancer as a primary disease domain.
RubyNanoMed's H2020 participation spans only 2020–2025, so their portfolio is early-stage. Their first project (PERSIST) placed them in the digital health and data space — cancer survivorship, patient data interoperability, and ethical AI. Their second project (BIOCELLPHE) shifted toward fundamental biosensing technology and FET (Future and Emerging Technologies) research, suggesting a move from applied clinical informatics toward deep-tech instrumentation. This trajectory points to a company consolidating around nanomedicine hardware — the biosensing platform — while retaining their oncology domain focus.
RubyNanoMed appears to be moving toward deep-tech nanotechnology instrumentation (biosensors, single-cell analysis) while keeping cancer diagnostics as their anchor application domain — making them an increasingly relevant partner for precision medicine consortia.
RubyNanoMed has never led a project — they enter as a specialist participant, contributing a specific technical capability to consortia assembled by larger institutions. With 24 unique partners across just 2 projects, they are embedded in medium-to-large consortia (roughly 12 partners per project on average), which is typical for RIA grants where broad, multi-disciplinary teams are required. Working with them likely means engaging a focused SME that delivers a well-defined component — biosensing hardware or data tools — rather than a generalist collaborator.
RubyNanoMed has built a surprisingly broad network for a two-project SME: 24 unique partners spanning 11 countries. This suggests they have been placed within well-connected international consortia and are not isolated within the Portuguese research ecosystem.
RubyNanoMed occupies a rare position as a Portuguese deep-tech SME operating simultaneously in clinical oncology informatics and nanoscale biosensing instrumentation — two fields that rarely appear in the same company profile at this scale. Their FET project participation (BIOCELLPHE) signals that major research institutions consider their technology credible enough for frontier research grants, which is a meaningful signal for a small private company. For consortium builders, they offer a compact, specialized contributor that brings nanomedicine tooling without the overhead of a large institute.
